WO1998024782A3 - Substituted pyrimidine compounds and their use - Google Patents
Substituted pyrimidine compounds and their use Download PDFInfo
- Publication number
- WO1998024782A3 WO1998024782A3 PCT/US1997/022390 US9722390W WO9824782A3 WO 1998024782 A3 WO1998024782 A3 WO 1998024782A3 US 9722390 W US9722390 W US 9722390W WO 9824782 A3 WO9824782 A3 WO 9824782A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- diseases
- substituted pyrimidine
- pyrimidine compounds
- maladies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019997005021A KR20000069328A (en) | 1997-06-13 | 1997-12-04 | Substituted pyrimidine compounds and their use |
CA002274063A CA2274063C (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
EP97954778A EP0948497A2 (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
NZ335997A NZ335997A (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds for treating TNF and interleukin diseases |
JP52585098A JP2002514195A (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and uses thereof |
IL13018097A IL130180A0 (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
AU60120/98A AU733877C (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
BR9713850-9A BR9713850A (en) | 1996-12-05 | 1997-12-04 | Compound, pharmaceutical composition, processes for prophylaxis or treatment of infection and diseases, to decrease plasma concentrations of either or both tnf-. and o; -1 of either or both il-6 and il-8, for the prophylaxis or treatment of diabetes disease and a pain disorder in a mammal, to decrease prostaglandin production in a mammal, and to decrease the activity of the enzyme cyclooxygenase in a mammal. |
HU0001698A HUP0001698A3 (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3212896P | 1996-12-05 | 1996-12-05 | |
US5095097P | 1997-06-13 | 1997-06-13 | |
US60/032,128 | 1997-06-13 | ||
US60/050,950 | 1997-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998024782A2 WO1998024782A2 (en) | 1998-06-11 |
WO1998024782A3 true WO1998024782A3 (en) | 1998-08-27 |
Family
ID=26708010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/022390 WO1998024782A2 (en) | 1996-12-05 | 1997-12-04 | Substituted pyrimidine compounds and their use |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2002514195A (en) |
AR (1) | AR038955A1 (en) |
TW (1) | TW520362B (en) |
WO (1) | WO1998024782A2 (en) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6489344B1 (en) * | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
AR023052A1 (en) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | DERIVATIVES OF PIRIMIDONA |
WO2000025791A1 (en) | 1998-11-04 | 2000-05-11 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
US6469018B1 (en) | 1999-01-08 | 2002-10-22 | Smithkline Beecham Corporation | Compounds |
US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
US7122666B2 (en) | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
AU2457201A (en) * | 1999-12-28 | 2001-07-09 | Bristol-Myers Squibb Company | Cytokine, especially tnf-alpha, inhibitors |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
AU2001262150A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
EP1136485A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Aminophenyl pyrimidone derivatives |
EP1136489A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperidin-1-yl]pyrimidone derivatives |
EP1136484A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Arylalkylamino)pyrimidone derivatives |
EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
EP1136491A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[(Heteroaryl)alkylamino]pyrimidone derivatives |
EP1136483A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
WO2001070727A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
EP1136493A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives |
EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
EP1136486A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives |
ATE284712T1 (en) | 2000-04-26 | 2005-01-15 | Eisai Co Ltd | MEDICINAL COMPOSITIONS FOR PROMOTING VITAL ACTIVATION |
MXPA02010993A (en) * | 2000-05-12 | 2003-03-10 | Genzyme Corp | MODULATORS OF TNF agr; SIGNALING. |
US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
GB0021494D0 (en) * | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
AU2001295026B2 (en) * | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
EP1345890A1 (en) | 2000-11-17 | 2003-09-24 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112810D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0119477D0 (en) * | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
EA007576B1 (en) | 2001-09-21 | 2006-12-29 | Мицубиси Фарма Корпорейшн | 3-substituted-4-pyrimidone derivatives |
CN1810802B (en) * | 2001-09-21 | 2011-04-27 | 三菱制药株式会社 | 3-substituted-4-pyrimidone derivatives |
US7572793B2 (en) | 2001-09-21 | 2009-08-11 | Mitsubishi Tanabe Pharma Corporation | 3-Substituted-4-pyrimidone derivatives |
TWI330183B (en) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
TW200302728A (en) | 2002-02-01 | 2003-08-16 | Novartis Ag | Substituted amines as IgE inhibitors |
AU2003213184A1 (en) | 2002-02-22 | 2003-09-09 | Pharmacia And Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
ATE309247T1 (en) * | 2002-02-28 | 2005-11-15 | Sanofi Aventis | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO(1,2-A)PYRIMIDINE-4-ONE DERIVATIVES |
US20030225075A1 (en) * | 2002-04-10 | 2003-12-04 | Orchid Chemicals & Pharmaceuticals Limited | Novel pyrimidone derivatives |
CA2485166A1 (en) * | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds |
AU2003245989A1 (en) | 2002-07-09 | 2004-01-23 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
ES2263058T3 (en) | 2002-08-19 | 2006-12-01 | Glaxo Group Limited | PIRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS. |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
MXPA05006394A (en) | 2002-12-16 | 2007-04-16 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives. |
EP1592695A1 (en) * | 2003-02-06 | 2005-11-09 | Basf Aktiengesellschaft | Pyrimidines, methods for the production thereof, and use thereof |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
JP2007534624A (en) * | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | Biaryl piperazinyl-pyridine analogues |
JP2007502300A (en) * | 2003-08-13 | 2007-02-08 | カイロン コーポレイション | GSK-3 inhibitor and use thereof |
US7429594B2 (en) | 2003-08-20 | 2008-09-30 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
GB0323137D0 (en) | 2003-10-03 | 2003-11-05 | Chang Lisa C W | 2,4,6- Trisubstituted pyrimidines and their different uses |
CA2562244A1 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
AU2006259525B2 (en) * | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
ES2270715B1 (en) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRAZINA. |
WO2007022964A2 (en) | 2005-08-24 | 2007-03-01 | Abbott Gmbh & Co. Kg | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors |
ES2274712B1 (en) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | NEW IMIDAZOPIRIDINE DERIVATIVES. |
TW200831491A (en) | 2006-10-10 | 2008-08-01 | Amgen Inc | N-aryl pyrazole compounds, compositions, and methods for their use |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
EP2173722B1 (en) * | 2007-07-26 | 2012-08-29 | Novartis AG | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
AU2008355098B2 (en) | 2008-04-21 | 2012-11-15 | Gpcr Therapeutics, Inc | Heterocyclic compounds |
WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
WO2012054535A2 (en) | 2010-10-18 | 2012-04-26 | Cerenis Therapeutics Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
EP2655331A1 (en) | 2010-12-23 | 2013-10-30 | Pfizer Inc | Glucagon receptor modulators |
PT2673260T (en) | 2011-02-08 | 2016-10-24 | Pfizer | Glucagon receptor modulator |
CN103732578B (en) | 2011-07-22 | 2015-08-12 | 辉瑞大药厂 | Quinolinyl glucagon receptor conditioning agent |
EP2776405A1 (en) | 2011-11-11 | 2014-09-17 | Pfizer Inc | 2-thiopyrimidinones |
ES2663806T3 (en) | 2013-12-19 | 2018-04-17 | unshine Lake Pharma Co., Ltd. | Heterocyclic nitrogen derivatives and their application in the treatment of tissue fibrosis |
TWI651310B (en) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | Triterpenoids and their medical use |
BR112017022340A2 (en) | 2015-05-05 | 2018-07-10 | Pfizer | 2-thiopyrimidinones |
DK3372589T3 (en) * | 2015-10-29 | 2021-12-06 | Aska Pharm Co Ltd | Pyrimidine derivatives |
RU2022100782A (en) * | 2015-11-04 | 2022-02-03 | Мерк Патент Гмбх | METHODS FOR CANCER TREATMENT USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITOR ACTIVITY |
UA123159C2 (en) * | 2015-11-17 | 2021-02-24 | Мерк Патент Гмбх | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
TW201811766A (en) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease |
CN114981243A (en) * | 2019-11-12 | 2022-08-30 | 健赞公司 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficiency of CFTR activity |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1271116B (en) * | 1965-05-04 | 1968-06-27 | Bayer Ag | Process for the preparation of 4-hydroxypyrimidines |
DE2056407A1 (en) * | 1969-11-20 | 1971-05-27 | Sandoz Ag, Basel (Schweiz) | Process for the preparation of 1 alkyl 4,5 diphenyl or 4 (2 thienyl) 5 phenyl pynmidin 2 (1H) ones |
US4438117A (en) * | 1980-09-03 | 1984-03-20 | E. I. Du Pont De Nemours And Company | 2-Substituted thio-4,5-diarylpyrimidines |
DE3319843A1 (en) * | 1983-06-01 | 1984-12-06 | Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal | Process for the preparation of pyrimidines from nitrile and alkynes |
EP0130046A1 (en) * | 1983-06-22 | 1985-01-02 | Eli Lilly And Company | Pyrimidine derivatives |
US5077142A (en) * | 1989-04-20 | 1991-12-31 | Ricoh Company, Ltd. | Electroluminescent devices |
WO1996003387A1 (en) * | 1994-07-28 | 1996-02-08 | G.D. Searle & Co. | 4,5-substituted imidazolyl compounds for the treatment of inflammation |
WO1997012876A1 (en) * | 1995-10-06 | 1997-04-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
WO1997016442A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1997033883A1 (en) * | 1996-03-13 | 1997-09-18 | Smithkline Beecham Corporation | Novel pyrimidine compounds useful in treating cytokine mediated diseases |
-
1997
- 1997-12-04 AR ARP970105716A patent/AR038955A1/en not_active Application Discontinuation
- 1997-12-04 TW TW086118244A patent/TW520362B/en not_active IP Right Cessation
- 1997-12-04 JP JP52585098A patent/JP2002514195A/en active Pending
- 1997-12-04 WO PCT/US1997/022390 patent/WO1998024782A2/en active IP Right Grant
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1271116B (en) * | 1965-05-04 | 1968-06-27 | Bayer Ag | Process for the preparation of 4-hydroxypyrimidines |
DE2056407A1 (en) * | 1969-11-20 | 1971-05-27 | Sandoz Ag, Basel (Schweiz) | Process for the preparation of 1 alkyl 4,5 diphenyl or 4 (2 thienyl) 5 phenyl pynmidin 2 (1H) ones |
US4438117A (en) * | 1980-09-03 | 1984-03-20 | E. I. Du Pont De Nemours And Company | 2-Substituted thio-4,5-diarylpyrimidines |
DE3319843A1 (en) * | 1983-06-01 | 1984-12-06 | Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal | Process for the preparation of pyrimidines from nitrile and alkynes |
EP0130046A1 (en) * | 1983-06-22 | 1985-01-02 | Eli Lilly And Company | Pyrimidine derivatives |
US5077142A (en) * | 1989-04-20 | 1991-12-31 | Ricoh Company, Ltd. | Electroluminescent devices |
WO1996003387A1 (en) * | 1994-07-28 | 1996-02-08 | G.D. Searle & Co. | 4,5-substituted imidazolyl compounds for the treatment of inflammation |
WO1997012876A1 (en) * | 1995-10-06 | 1997-04-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
WO1997016442A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1997033883A1 (en) * | 1996-03-13 | 1997-09-18 | Smithkline Beecham Corporation | Novel pyrimidine compounds useful in treating cytokine mediated diseases |
Non-Patent Citations (6)
Title |
---|
G. B. BENNETT ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 21, no. 7, 1978, pages 623 - 8, XP000612140 * |
H.-J. KABBE, LIEBIGS ANNALEN DER CHEMIE, vol. 704, 1967, pages 144 - 9, XP002065898 * |
L. GIAMMANCO ET AL., ANNALI DI CHIMICA, vol. 60, no. 3, March 1970 (1970-03-01), pages 188 - 97, XP002064349 * |
L. GIAMMANCO, ATTI DELLA ACCADEMIA DI SCIENZE LETTERE E ARTI DI PALERMO, vol. 27, 1968, pages 469 - 83, XP002064350 * |
M. TAKAHASHI ET AL., HETEROCYCLES, vol. 22, no. 3, 1984, pages 581 - 4, XP002064343 * |
R. J. IFE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 6, 1995, pages 543 - 6, XP002065899 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998024782A2 (en) | 1998-06-11 |
AR038955A1 (en) | 2005-02-02 |
TW520362B (en) | 2003-02-11 |
JP2002514195A (en) | 2002-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998024782A3 (en) | Substituted pyrimidine compounds and their use | |
WO1999032448A8 (en) | Substituted pyridine and pyridazine compounds and their pharmaceutical use | |
WO1998024780A3 (en) | Substituted pyrimidinone and pyridinone compounds and their use | |
WO2003044021A3 (en) | Substituted indolizine-like compounds and methods of use | |
PT948495E (en) | ANTI-INFLAMMATORY AGENTS OF FUSED PYRROLE SUBSTITUTED IN ARYL AND HETEROARYL | |
WO2002014311A3 (en) | Urea compounds and methods of uses | |
DE69838070D1 (en) | SUBSTITUTED PYRIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | |
IL172419A0 (en) | Piperazine derivatives and methods of use | |
WO2004007457A3 (en) | Substituted benzylamine derivatives and methods of use | |
RS60503A (en) | Substituted alkylamine derivatives and methods of use | |
WO2004005279A3 (en) | Substituted anthranilic amide derivatives and methods of use | |
FI20115753A (en) | Pharmaceutical compositions for the treatment of diseases caused by IL-6 production | |
WO2004092116A8 (en) | Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof | |
MXPA05010883A (en) | Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin. | |
CA2274063A1 (en) | Substituted pyrimidine compounds and their use | |
WO2006041888A3 (en) | Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents | |
EP1314732A3 (en) | Substituted pyrimidine compounds and their use | |
AP2000001793A0 (en) | Novel polymorph forms. | |
PL373842A1 (en) | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders | |
EP1619184A3 (en) | Urea compounds as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97181563.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 335997 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 60120/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2274063 Country of ref document: CA Ref document number: 2274063 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/005168 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-2015 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997005021 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997954778 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954778 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-2015 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997005021 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 60120/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997954778 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997005021 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-2015 Country of ref document: CZ |